Ehrsson H - Search Results

1

Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.

Gullbo J, Dhar S, Luthman K, Ehrsson H, Lewensohn R, Nygren P, Larsson R. Gullbo J, et al. Among authors: ehrsson h. Anticancer Drugs. 2003 Sep;14(8):617-24. doi: 10.1097/00001813-200309000-00006. Anticancer Drugs. 2003. PMID: 14501383

2

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.

Gullbo J, Wickström M, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R. Gullbo J, et al. Among authors: ehrsson h. J Drug Target. 2003 Jul;11(6):355-63. doi: 10.1080/10611860310001647140. J Drug Target. 2003. PMID: 14668056

3

Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.

Gullbo J, Wallinder C, Tullberg M, Lövborg H, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R. Gullbo J, et al. Among authors: ehrsson h. Mol Cancer Ther. 2003 Dec;2(12):1331-9. Mol Cancer Ther. 2003. PMID: 14707274

4

Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.

Gullbo J, Tullberg M, Våbenø J, Ehrsson H, Lewensohn R, Nygren P, Larsson R, Luthman K. Gullbo J, et al. Among authors: ehrsson h. Oncol Res. 2003;14(3):113-32. doi: 10.3727/000000003771013071. Oncol Res. 2003. PMID: 14760861

5

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Gullbo J, Lindhagen E, Bashir-Hassan S, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, De La Torre M, Luthman K, Larsson R. Gullbo J, et al. Among authors: ehrsson h. Invest New Drugs. 2004 Nov;22(4):411-20. doi: 10.1023/B:DRUG.0000036683.10945.bb. Invest New Drugs. 2004. PMID: 15292711

6

Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.

Larsson R, Dhar S, Ehrsson H, Nygren P, Lewensohn R. Larsson R, et al. Among authors: ehrsson h. Br J Cancer. 1998 Aug;78(3):328-35. doi: 10.1038/bjc.1998.494. Br J Cancer. 1998. PMID: 9703278 Free PMC article.

7

Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin.

Videhult P, Yachnin J, Jerremalm E, Lewensohn R, Ehrsson H. Videhult P, et al. Among authors: ehrsson h. Cancer Lett. 2002 Jun 28;180(2):191-4. doi: 10.1016/s0304-3835(02)00002-2. Cancer Lett. 2002. PMID: 12175551

8

The kinetics and cytotoxicity of cisplatin and its monohydrated complex.

Yachnin JR, Wallin I, Lewensohn R, Sirzén F, Ehrsson H. Yachnin JR, et al. Among authors: ehrsson h. Cancer Lett. 1998 Oct 23;132(1-2):175-80. doi: 10.1016/s0304-3835(98)00175-x. Cancer Lett. 1998. PMID: 10397471

9

Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.

Lewensohn R, Fernberg JO, Ehrsson H, Merlini G. Lewensohn R, et al. Among authors: ehrsson h. Med Oncol Tumor Pharmacother. 1991;8(4):265-9. doi: 10.1007/BF02987196. Med Oncol Tumor Pharmacother. 1991. PMID: 1820493

10

Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines.

Lewensohn R, Ehrsson H, Hansson J, Ringborg U. Lewensohn R, et al. Among authors: ehrsson h. Anticancer Res. 1991 Jan-Feb;11(1):321-4. Anticancer Res. 1991. PMID: 2018366

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

258 results

Search Page

Filters